Home Latest Articles
Latest Articles
  • Ping YU, Penghua ZHANG, Hongqin KE, Huan LIANG, Wenbin LIANG, Zhifang YU
    World Clinical Drug. 2024, 45(12): 1258-1262.
    Objective

    To explore the therapeutic effect of Dengtaiye granules combined with glycine theophylline sodium sustained-release tablets in the treatment of acute exacerbation of chronic asthmatic bronchitis.

    Methods

    106 patients with acute exacerbation of chronic asthmatic bronchitis admitted to Shiyan Taihe Hospital from April 2021 to December 2023 were selected and divided into the control group and the treatment group, and 53 cases in each group. The control group was treated with glycine theophylline sodium sustained-release tablets, and the treatment group was treated with Dengtaiye granules combined with glycine theophylline sodium sustained-release tablets. The therapeutic effects, the improvement time of traditional Chinese medicine symptoms, serum inflammation indicators, and adverse reactions between two groups were compared after 7 days of treatment.

    Results

    The total effective rate of the treatment group was higher than that of the control group (96.23% vs 84.91%, P<0.05). The improvement time of cough, phlegm accumulation, wheezing, facial redness and irritability, and dry stools in the treatment group was shorter than that in the control group (P<0.05). After treatment, C-reactive protein, interleukin (IL)-6, IL-17, and tumor necrosis factor-α were decreased in the two groups (P<0.05), and the treatment group were lower than those in the control group (P<0.05). There was no significant difference in the incidence of adverse reactions between the two groups (P>0.05).

    Conclusion

    Dengtaiye granules combined with glycine theophylline sodium sustained-release tablets can achieve ideal therapeutic effects in the treatment of acute exacerbation of chronic asthmatic bronchitis. It can quickly improve the traditional Chinese medicine symptoms of patients, effectively reduce the inflammatory response in the body, and has high safety.

  • Na LI, Zhijie YAO, Fenghui MA, Hua BAI
    World Clinical Drug. 2024, 45(12): 1263-1268.
    Objective

    To investigate the effects of fecal microbiota capsules in the adjuvant treatment of low-risk membranous nephropathy (MN) and its influence on T cell subsets and renal function.

    Methods

    A total of 90 low-risk MN patients admitted to our hospital from January 2022 to January 2024 were selected and divided into control group and experimental group by random number table method, with 45 cases in each group. The control group was treated with routine treatment, and the experimental group was treated with fecal microbiota capsules on the basis of routine treatment. The intestinal flora distribution, flora disorder grade, T lymphocyte level, cluster of differentiation antigen (CD)4+, CD8+, CD4+/CD8+ levels and renal function related indexes were compared between the two groups before and after treatment.

    Results

    Before treatment, there were no significant differences in intestinal flora distribution, flora disorder grade, T lymphocytes, CD4+, CD8+, CD4+/CD8+ and renal function indexes between the two groups (P>0.05). After treatment, the number of lactobacillus, bacteroides, bifidobacterium, normal flora, number of degree Ⅰ disorder, T helper cell (Th)2, regulatory T cells, CD4+, CD8+, CD4+/CD8+ and epidermal growth factor receptor in experimental group were higher than those in control group. The levels of

    Coccobacillus

    and Escherichia coli, the number of degree Ⅲ disorders, Th1, Th17, urea nitrogen, serum creatinine, anti-phospholipase A2 receptor antibody and type Ⅰ platelet reactive protein 7A domain were lower than those of control group (P<0.05). Conclusion Fecal microbiota capsules can help regulate the balance of intestinal flora, improve T cell subsets and renal function in the treatment of low-risk MN.

  • Aifen LU, Guijia ZHU, Zhikuan FENG, Junyou LIU, Ke ZHANG
    World Clinical Drug. 2024, 45(12): 1269-1275.
    Objective

    To observe the effect of vericiguat combined with dapagliflozin in patients with heart failure with reduced ejection fraction (HFrEF).

    Methods

    A total of 98 patients with HFrEF in our hospital from January 2023 to January 2024 were selected and divided into combination group and control group according to random number table method, with 49 cases in each group. On the basis of conventional HF treatment, the control group was given dapagliflozin, the combination group was given dapagliflozin combined with vericiguat. Both groups were treated for 6 months. The clinical effect, adverse reactions, HF rehospitalization rate and major adverse cardiovascular event (MACE) were compared between the two groups. The cardiac function indexes, N-terminal brain natriuretic peptide precursor (NT-proBNP), neutrophil-to-lymphocyte ratio (NLR), C-reactive protein (CRP), Minnesota living with heart failure questionnaire (MLHFQ) score, 6-minute walking test (6MWT) distance were compared between the two groups before and after treatment.

    Results

    After treatment, the total effective rate of combination group was higher than that of control group (93.62% vs 70.83%, P<0.05). The LVEF level and 6MWT distance were increased in both groups, and the combination group was higher than the control group (P<0.05). The levels of LVEDD, LVESD, NT-proBNP, NLR, CRP and MLHFQ score were all decreased, and the combination group was lower than the control group (P<0.05). There was no significant difference in the occurrence of adverse reactions between the two groups (P<0.05). The incidence of HF rehospitalization (6.38% vs 20.83%, P<0.05) and MACE (12.77% vs 31.25%, P<0.05) in the combination group were lower than those in the control group, respectively.

    Conclusion

    Vericiguat combined with dapagliflozin can significantly reduce ventricular remodeling and inflammatory response in HFrEF patients, enhance efficacy, improve quality of life and prognosis, and have good safety.

  • Cong WANG, Yuxia ZHANG, Fahui GUO, Qian LI, Wenxiu MA, Xueping HAN
    World Clinical Drug. 2024, 45(12): 1276-1280.
    Objective

    To investigate the clinical effect of eltrombopag combined with standard immunosuppression in the treatment of aplastic anemia (AA) and its effect on GATA binding protein (GATA)-3, transforming growth factor (TGF)-β and soluble Fas (sFas) level.

    Methods

    A total of 175 patients with AA in our hospital from January 2020 to December 2023 were selected and divided into observation group (n=88) and control group (n=87). The control group was treated with standard immunosuppressive therapy, and the observation group was treated with eltrombopag on the basis of the control group. The clinical efficacy, GATA-3, TGF-β, sFas, platelet count (PLT), white blood cell (WBC), immune function and adverse reactions were compared between the two groups.

    Results

    After treatment, the total effective rate of observation group was higher than that of control group (92.05% vs 81.61%, P<0.05). Serum levels of GATA-3, TGF-β and sFas in both groups were significantly decreased (P<0.05), and the observation group was lower than the control group (P<0.05). The levels of PLT and WBC in both groups were significantly higher than before (P<0.05), and the observation group was higher than the control group (P<0.05). The cluster of differentiation (CD)4+ and CD4+/CD8+ in both groups were significantly decreased than before (P<0.05), and the observation group was lower than the control group (P<0.05), while CD8+ was significantly increased than before (P<0.05), and the observation group was higher than the control group (P<0.05). During treatment, there was no significant difference in adverse reactions between the two groups (P>0.05).

    Conclusion

    Eltrombopag combined with standard immunosuppressive therapy in AA is more effective, and can improve the serum levels of GATA-3, TGF-β and sFas.

  • Haiying TENG, Yang WANG, Ming HUANG
    World Clinical Drug. 2024, 45(12): 1281-1286.
    Objective

    To investigate the therapeutic effect of ginkgo biloba diterpene lactone meglumine injection combined with acupuncture through tendons on hemiplegia patients with stroke and its effects on cyclic adenosine phosphate (cAMP), cyclic guanosine phosphate (cGMP) and brain-derived neurotrophic factor (BDNF) in serum.

    Methods

    A total of 150 stroke patients with hemiplegia in our hospital from March 2022 to March 2024 were selected and divided into observation group (conventional treatment+ginkgo biloba diterpenoid lactone meglumine injection+acupuncture through tendons) and control group (conventional treatment+ginkgo biloba diterpenoid lactone meglumine injection) according to random number table method, 75 cases in each group, and both groups were treated for 8 weeks. The clinical efficacy, serum cAMP, cGMP, BDNF, and scores of National Institute of Health stroke scale (NIHSS), Fugl-Meyer motor function assessment (FMA) and traditional Chinese medicine syndrome scores were compared between the two groups.

    Results

    The total effective rate of observation group was higher than that of control group (88.00% vs 70.67%, P<0.05). Serum cAMP and BDNF in observation group were higher than those in control group (P<0.05), and cGMP was lower than that in control group (P<0.05). The NIHSS score of the observation group was lower than that of the control group (P<0.05), and the FMA score was higher than that of the control group (P<0.05). The syndrome scores of hemiplegia, tongue deviation, and speech astringency syndrome in the observation group were lower than those in the control group (P<0.05).

    Conclusion

    Ginkgo biloba diterpene lactone meglumine injection combined with acupuncture through tendons has a significant effect in the treatment of hemiplegia after stroke. The two have a synergistic effect, which can regulate the levels of serum cAMP, cGMP and BDNF, and promote functional recovery.

  • Aijun HE, Bo CAO, Xiaobao LI, Yu Ren
    World Clinical Drug. 2024, 45(12): 1287-1291.
    Objective

    To investigate the effect of traditional Chinese medicine (TCM) fumigation and washing combined with laparoscopic natural orifice specimen extraction surgery on posterior anal function and pain index in patients with low rectal cancer.

    Methods

    A total of 94 male patients with low rectal cancer admitted to our hospital from September 2020 to October 2022 were selected. The patients were divided into two groups according to random number table method. The control group was treated with laparoscopic natural orifice specimen extraction surgery, and the study group was treated with TCM fumigation and washing intervention based on the control group. The urination function, incidence of postoperative anastomotic stenosis and anastomotic fistula and visual analogue pain score were compared between the two groups.

    Results

    After the intervention, the visual analogue pain score of the study group was significantly lower than that of the control group (t=3.592, P<0.001), and the detrusor pressure at maximum flow rate and the maximum urethral closure pressure were better than those in the control group (P<0.05).

    Conclusion

    TCM fumigation and washing intervention can effectively reduce the postoperative pain of male patients with laparoscopic resection of low rectal cancer, and improve their urination function and postoperative rehabilitation quality.

  • Tianqi QIAO, Yijian CUI, Yining LUO, Yanxia GAO, Haijun ZHAO, Jing LU
    World Clinical Drug. 2024, 45(12): 1292-1299.
    Objective

    To investigate the effects of subcutaneous injection of granulocyte colony-stimulating factor (G-CSF) combined with low molecular weight heparin (LMWH) on the clinical pregnancy outcome of freeze-thaw embryo transfer (FET) in patients with unexplained repeated implantation failure (URIF) during in vitro fertilization/intracytoplasmic sperm injection (IVF/ICSI) cycles.

    Methods

    The data of URIF patients who underwent IVF/ICSI in the department of reproductive medicine of Handan central hospital from January 2017 to March 2023 were analyzed, according to the treatment methods, group A received subcutaneous injection of G-CSF combined with LMWH during FET cycle, group B received subcutaneous injection of G-CSF, group C received subcutaneous injection of LMWH, group D received conventional luteal support therapy. According to the patients' basic data, the propensity score matching was performed, and the caliper value was set to 0.02. The FET cycle characteristics, clinical pregnancy outcome, obstetric outcome and neonatal outcome and major adverse reactions were compared.

    Results

    There was no statistical significance in the characteristics of patients in each group during the FET cycle (P>0.05). There were significant differences in embryo implantation rate, clinical pregnancy rate and β-human chorionic gonadotropin (HCG) positive rate among all groups (P=0.002, P=0.006, P=0.007). There were no significant differences in term birth rate, preterm birth rate, twin rate, obstetric complications rate (pregnation-induced hypertension rate, premature rupture rate) and neonatal complications rate (macrosomia rate, low birth weight rate) among all groups (P>0.05).

    Conclusion

    G-CSF combined LMWH subcutaneously can improve the embryos grow rate, clinical pregnancy rate and β-HCG positive rate of FET cycle in URIF patients, which is an effective treatment.

  • Lei QIN, Jie XU
    World Clinical Drug. 2024, 45(12): 1300-1302.
  • Jianing GE, Fenghua GU
    World Clinical Drug. 2024, 45(12): 1303-1308.

    Chronic bronchitis (CB) is a widespread respiratory disease, and its core pathogenesis revolves around the inflammatory response. A vicious cycle is formed between this inflammatory response and oxidative stress, leading to a series of complex pathological changes such as excessive mucus secretion, airway surface dehydration, and airway fibrosis remodeling. Among them, the molecular mechanisms are interrelated and jointly promote the development of the disease. This article comprehensively analyzed the role of inflammatory response in CB and its various pathological manifestations, aiming to provide improved ideas for existing treatment methods, stimulated the development of new drugs, and effectively transform basic scientific research results into clinical practice, so as to bring more effective treatment strategies for CB patients.

  • Zhongyin ZHANG, Tingting HU, Chenji HU, Linshan JIANG, Xinyi WANG
    World Clinical Drug. 2024, 45(12): 1309-1313.

    Diabetic kidney disease (DKD) is a type of kidney disease caused by diabetes mellitus, which seriously affects the quality of life of patients and poses a major burden on the global health economy. Non-steroidal corticosteroid receptor antagonist (MRA) is a novel drug for the treatment of DKD, which has the potential to reduce cardiovascular events and delay the deterioration of renal function. Compared with traditional DKD agents, non-steroidal MRA can more effectively slow down the inflammatory reaction and fibrotic processes, and reduce the incidence of hyperkalemia. This article reviewed the recent progress of non-steroidal MRA's efficacy in DKD, aiming to provide safer and more effective treatment options for DKD patients.

News